4 ms·
DMSO produces dimethyl sulfide in the body when it is metabolized. To say there is no effect of dimethyl sulfide is to not know human biology or health. Therefo
by FollowingTheDao 2y ago
DMSO produces dimethyl sulfide in the body when it is metabolized. To say there is no effect of dimethyl sulfide is to not know human biology or health. Therefore DMSO could play a role as a medicine and it is currently still an area of research for cancer.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9801450/ https://pmc.ncbi.nlm.nih.gov/articles/PMC9801450/
http://bmrat.com/index.php/BMRAT/article/view/614 http://bmrat.com/index.php/BMRAT/article/view/614
As well as an overall immunomodulary agent:
https://www.sciencedirect.com/science/article/pii/S0171298519303729 https://www.sciencedirect.com/science/article/pii/S017129851...
I am not, of course, suggesting that everyone take DMSO, but the fact is that this very cheap molecule is not studied for one reason; it cannot be patented. And since it is possible that the pharmaceutical companies might know this, banning it would give them time for drug discovery and a patent on a molecule that acts similarly to DMSO.
It is a fact that the FDA gets nearly half of its funding from corporations it regulates.
https://today.uconn.edu/2021/05/why-is-the-fda-funded-in-part-by-the-companies-it-regulates-2/ https://today.uconn.edu/2021/05/why-is-the-fda-funded-in-par...
You at least should have a skeptical eye when it come to the FDA banning a molecule like DMSO. I can understand regulating it, but banning it was an over reaction by the FDA.
https://www.mcgill.ca/oss/article/medical-critical-thinking-history/dmso-not-cure-all-fdas-panic-over-it-birthed-myth https://www.mcgill.ca/oss/article/medical-critical-thinking-...
"These companies wanted to put DMSO through its paces and eventually market it as a drug."
- ttyprintk 2y agoNitpick on the funding: the departments testing human drugs and biologics are 66 and 40% funded by fees, as opposed to taxpayers. They or Congress could decide to drop the fees for a high-priority submission.